Linked Life Data

11292619

Source:http://linkedlifedata.com/resource/pubmed/id/11292619

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11292619rdf:typepubmed:Citationlld:pubmed
pubmed-article:11292619lifeskim:mentionsumls-concept:C0003009lld:lifeskim
pubmed-article:11292619lifeskim:mentionsumls-concept:C1456820lld:lifeskim
pubmed-article:11292619lifeskim:mentionsumls-concept:C0151650lld:lifeskim
pubmed-article:11292619lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:11292619lifeskim:mentionsumls-concept:C1880177lld:lifeskim
pubmed-article:11292619pubmed:issue5lld:pubmed
pubmed-article:11292619pubmed:dateCreated2001-4-9lld:pubmed
pubmed-article:11292619pubmed:abstractTextAngiotensin II upregulates tumor necrosis factor-alpha (TNF-alpha) in the rat kidney with unilateral ureteral obstruction (UUO). In a mouse model of UUO, we found that tubulointerstitial fibrosis is blunted when the TNF-alpha receptor, TNFR1, is functionally knocked out. In this study, we used mutant mice with UUO in which the angiotensin II receptor AT(1a) or the TNF-alpha receptors TNFR1 and TNFR2 were knocked out to elucidate interactions between the two systems. The contribution of both systems to renal fibrosis was assessed by treating TNFR1/TNFR2-double knockout (KO) mice with an angiotensin-converting enzyme inhibitor, enalapril. The increased interstitial volume (Vv(int)) in the C57BI/6 wild-type mouse was decreased in the AT(1a) KO from 32.8 +/- 4.0 to 21.0 +/- 3.7% (P < 0.005) or in the TNFR1/TNFR2 KO to 22.3 +/- 2.1% (P < 0.005). The Vv(int) of the TNFR1/TNFR2 KO was further decreased to 15.2 +/- 3.7% (P < 0.01) by enalapril compared with no treatment. The induction of TNF-alpha mRNA and transforming growth factor-beta1 (TGF-beta1) mRNA in the kidney with UUO was significantly blunted in the AT(1a) or TNFR1/TNFR2 KO mice compared with the wild-type mice. Treatment of the TNFR1/TNFR2 KO mouse with enalapril reduced both TNF-alpha and TGF-beta1 mRNA and their proteins to near normal levels. Also, alpha-smooth muscle actin expression and myofibroblast proliferation were significantly inhibited in the AT(1a) or TNFR1/TNFR2 KO mice, and they were further inhibited in enalapril-treated TNFR1/TNFR2 KO mice. Incapacitating the angiotensin II or the TNF-alpha systems individually leads to partial blunting of fibrosis. Incapacitating both systems, by using a combination of genetic and pharmacological means, further inhibited interstitial fibrosis and tubule atrophy in obstructive nephropathy.lld:pubmed
pubmed-article:11292619pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:languageenglld:pubmed
pubmed-article:11292619pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:citationSubsetIMlld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11292619pubmed:statusMEDLINElld:pubmed
pubmed-article:11292619pubmed:monthMaylld:pubmed
pubmed-article:11292619pubmed:issn1931-857Xlld:pubmed
pubmed-article:11292619pubmed:authorpubmed-author:KlahrSSlld:pubmed
pubmed-article:11292619pubmed:authorpubmed-author:MorrisseyJJlld:pubmed
pubmed-article:11292619pubmed:authorpubmed-author:GuyMMlld:pubmed
pubmed-article:11292619pubmed:authorpubmed-author:McCrackenRRlld:pubmed
pubmed-article:11292619pubmed:authorpubmed-author:LiapisHHlld:pubmed
pubmed-article:11292619pubmed:authorpubmed-author:TolleyTTlld:pubmed
pubmed-article:11292619pubmed:issnTypePrintlld:pubmed
pubmed-article:11292619pubmed:volume280lld:pubmed
pubmed-article:11292619pubmed:ownerNLMlld:pubmed
pubmed-article:11292619pubmed:authorsCompleteYlld:pubmed
pubmed-article:11292619pubmed:paginationF777-85lld:pubmed
pubmed-article:11292619pubmed:dateRevised2011-4-28lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:meshHeadingpubmed-meshheading:11292619...lld:pubmed
pubmed-article:11292619pubmed:year2001lld:pubmed
pubmed-article:11292619pubmed:articleTitleContributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis.lld:pubmed
pubmed-article:11292619pubmed:affiliationDepartments of Internal Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, 216 S. Kingshighway Blvd., St. Louis, Missouri 63110-1092, USA.lld:pubmed
pubmed-article:11292619pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11292619pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
entrez-gene:11606entrezgene:pubmedpubmed-article:11292619lld:entrezgene
entrez-gene:11607entrezgene:pubmedpubmed-article:11292619lld:entrezgene
entrez-gene:21926entrezgene:pubmedpubmed-article:11292619lld:entrezgene
entrez-gene:21937entrezgene:pubmedpubmed-article:11292619lld:entrezgene
entrez-gene:21938entrezgene:pubmedpubmed-article:11292619lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11292619lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11292619lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11292619lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11292619lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11292619lld:pubmed